Hydantoin hydrolase with responsibility for the ring opening of hydantoin is one of the components of hydantoin utility enzymes of Arthrobacter BT801 which can convert 5-benzylhydantoin into L-phenylalanine. The expression of hydantoin hydrolase gene (hyuH) is very important in elucidation of mechanisms of bio-catalysis and its application in asymmetry synthesis of amino acids. To improve the production and activity of the enzyme, the hydantoin hydrolase gene was amplified by PCR and cloned into E. coli by using vector pT221. The hydantoin hydrolase gene was highly expressed in E. coli BL21 (DE3) under the control of T7 promoter. A protein band about 50kD was detected by SDS-PAGE in the recombinant cell lysate. The objective protein in BL21 (DE3)/pT221-hyuH accounted for 40% of total cellular protein, mostly in soluble form. The products in the recombinant strain showed biological activity.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.
JAMA Netw Open
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Estimating the structural and spatial variables of allantoinase enzyme critical for protein adsorption.
Biochem Biophys Res Commun
January 2025
Jyoti and Bhupat Mehta School of Health Sciences and Technology, Indian Institute of Technology Guwahati, Assam, 781039, India; Centre for Nanotechnology, Indian Institute of Technology Guwahati, Assam, 781039, India. Electronic address:
Designing enzyme-based sensors necessitates a comprehensive exploration of macromolecular properties. Integrating enzymes with a suitable transducer involves immobilizing them onto a surface, facilitated through adsorption or entrapment techniques. Allantoin, a stable biomarkers metabolite, holds promise for detecting oxidative stress-related complications through its enzyme.
View Article and Find Full Text PDFEfficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer.
Prostate
February 2025
Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- The investigation focused on high-risk prostate cancer patients receiving neoadjuvant therapy before surgical procedures to assess clinical outcomes and factors influencing pathological responses.
- 76 patients were analyzed after receiving either androgen deprivation therapy with apalutamide or abiraterone, revealing significant differences in rates of pathological complete response and biochemical recurrence duration.
- Results showed that the apalutamide group had higher rates of complete response (51.5% vs. 25.6%) and longer biochemical recurrence duration (261 days vs. 76 days), with lower post-treatment PSA levels being a key predictor of favorable outcomes.
MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway.
Cell Commun Signal
October 2024
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Background: Enzalutamide (Enz) resistance is a poor prognostic factor for patients with castration-resistant prostate cancer (CRPC), which often involves aberrant expression of the androgen receptor (AR). Myosin VI (MYO6), one member of the myosin family, plays an important role in regulating cell survival and is highly expressed in prostate cancer (PCa). However, whether MYO6 is involved in Enz resistance in CRPC and its mechanism remain unclear.
View Article and Find Full Text PDFComparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.
Prostate
February 2025
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Article Synopsis
- The study evaluated the effectiveness and safety of three androgen receptor pathway inhibitors (ARPI) — abiraterone, enzalutamide, and apalutamide — in treating patients with metastatic hormone-sensitive prostate cancer in a real-world setting.
- Records of 668 high-risk patients treated with these drugs were analyzed, comparing prostate-specific antigen (PSA) responses, overall survival, and the incidence of adverse events.
- Results showed no significant differences in overall survival or cancer-specific survival among the three drugs, although abiraterone demonstrated a higher rate of achieving a 99% PSA decline, and enzalutamide had the lowest treatment discontinuation rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!